Scientists report a new method for establishing whether chemical compounds are safe for human use without "in vivo" testing, based on so-called "molecular initiating events" at the boundary between chemistry and biology.
Scientists have identified chemicals found in some everyday fruit that could protect vital organs from long-term damage following a heart attack or stroke, according to new research carried out in mice. The researchers now hope the chemicals will provide a starting point for developing new injectable drugs that could be used to prevent some of the long-term damage caused by heart attack and stroke.
Researchers at the University of Cambridge have managed to reconstruct the early stage of mammalian development using embryonic stem cells, showing that a critical mass of cells – not too few, but not too many – is needed for the cells to being self-organising into the correct structure for an embryo to form.
An experimental drug currently being trialled for influenza and Ebola viruses could have a new target: norovirus, often known as the winter vomiting virus. A team of researchers at the University of Cambridge has shown that the drug, favipiravir, is effective at reducing – and in some cases eliminating – norovirus infection in mice.
Vaccines against Salmonella that use a live, but weakened, form of the bacteria are more effective than those that use only dead fragments because of the particular way in which they stimulate the immune system, according to research from the University of Cambridge published today.
When a pregnant mother is undernourished, her child is at a greater than average risk of developing obesity and type 2 diabetes, in part due to so-called ‘epigenetic’ effects. A new study in mice demonstrates that this ‘memory’ of nutrition during pregnancy can be passed through sperm of male offspring to the next generation, increasing risk of disease for her grandchildren as well – in other words, to adapt an old maxim, ‘you are what your grandmother ate’.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.
Study illustrates “high conservation potential” of vaccines for endangered wild primates devastated by viral disease, but highlights need for access to captive chimpanzees so vaccines can be trialled before being administered in the wild.
A new technique developed at the University of Cambridge allows researchers to identify clusters of proteins on immune cells which are key to fighting off the body’s invaders.